Login to Your Account

Clinic Roundup

Tuesday, September 3, 2013
Ophthotech Corp., of New York, initiated enrollment in a pivotal Phase III trial of lead compound Fovista, an anti-platelet-derived growth factor, which is being studied in combination with anti-VEGF therapy to treat newly diagnosed neovascular age-related macular degeneration (wet AMD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription